Please login to the form below
Makena
This page shows the latest Makena news and features for those working in and with pharma, biotech and healthcare.
Overcoming quantitative pricing limitations
wrong. For example, in 2011, a company called KV Pharmaceuticals received orphan drugs status - and seven years of market exclusivity - for Makena, its own version of progesterone, used to reduce the ... The company set a price of $1, 500 per dose for
Latest news
-
Amag buys into maternal health business
Amag's primary objective in buying Lumara - which until this year was known as KV Pharmaceutical - is to gain ownership of Makena (hydroxyprogesterone caproate), a drug used in the management of ... The buoyant growth for Makena has come despite
-
March of Dimes cuts ties with KV Pharma
in protest over the company's pricing for Makena (hydroxyprogesterone caproate injection), a drug to prevent preterm birth that won US Food and Drug Administration (FDA) approval in February. ... Makena, which was formerly known as Gestiva, was developed
-
K-V preterm birth drug approved
Thirty-seven per cent of women treated with Makena delivered before 37 weeks, compared with 55 per cent of women in the control group. ... An international trial is ongoing to determine whether Makena reduces the number of babies who do not survive or
More from news
Approximately 1 fully matching, plus 3 partially matching documents found.
Latest Intelligence
-
Deal Watch table for September 2014
Maternal health business including orphan drug to reduce risk of preterm birth Makena.
-
Pharma deals during September 2014
KV Pharmaceuticals emerged from Chapter 11 bankruptcy in September 2013 with the new name Lumara Health and two divisions: maternal health for the orphan drug Makena; and women's health for ... The potential maximum sales multiple of 9 for Makena
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest appointments
-
KV Pharmaceutical names Joseph Mahady as chair
This financial state was due to the flawed launch of its drug Makena to prevent premature birth. ... The company seems to be back on track, however, after reaching a settlement with Hologic, the original developers of Makena who sold the rights to KV.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
-
Senior Medical Writer
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Technical Sales Representative
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- LEO Pharma enters clinical trial partnership with ICON
- Results for Astellas’ non-hormonal menopause drug published in The Lancet
- Roche’s Polivy backed by FDA Advisory Committee for lymphoma therapy
- Biogen and Eisai’s Alzheimer’s drug to be covered by US Veterans Health Administration
- Sanofi/Regeneron’s Dupixent shows promise in atopic hand and foot dermatitis
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- UCB's bimekizumab shows continued improvement in hidradenitis suppurativa patients
- The Considered appoints Bam Zahraie as chief experience officer
- The impact of pharma congresses on HCPs – virtual and in person
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- A relentless commitment to neuroscience
- Alzheon says data backs potential of Alzheimer's candidate
- BMS will not launch cancer drug Opdualag in Germany due to pricing pressures
- Regeneron’s application for Eylea in retinopathy of prematurity accepted for FDA priority review
PMHub
Onyx Health
Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...
Latest intelligence
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
- WHY ARE PATIENT SUPPORT PROGRAMMES NOT WORKING?
- By offering patients knowledge, skills and confidence, they empower patients to be more actively involved in their health. Holistic support can help tackle adherence, mental health or anything else patients...
